Published online before print May 14, 2007, doi: 10.1161/CIRCULATIONAHA.106.671420
(Circulation. 2007;115:2715-2721.)
© 2007 American Heart Association, Inc.
Coronary Heart Disease |
Local Production of Lipoprotein-Associated Phospholipase A2 and Lysophosphatidylcholine in the Coronary Circulation
Association With Early Coronary Atherosclerosis and Endothelial Dysfunction in Humans
From the Division of Cardiovascular Diseases (S.L., C.S.R., A.P., V.M., L.O.L., A.L.), Department of Laboratory Medicine and Pathology (J.P.M.), and Division of Nephrology and Hypertension (L.O.L.), Mayo Clinic, Rochester, Minn.
Correspondence to Amir Lerman, MD, Division of Cardiovascular Diseases, Mayo Clinic, Mary Brigh 4–523, First St SW, Rochester, MN 55905. E-mail Lerman.Amir{at}mayo.edu
Received October 19, 2006; accepted March 26, 2007.
Background— Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel marker and participant in vascular inflammation. Inflammation also is associated with coronary atherosclerosis. We tested the hypothesis that local coronary production of Lp-PLA2 is enhanced in patients with early coronary atherosclerosis and associated with local endothelial function.
Methods and Results— Coronary angiography, blood flow, flow reserve, endothelial function assessment, and intravascular ultrasound with volumetric analysis were performed in 15 patients with mild coronary atherosclerosis and in 15 control subjects. Plasma samples were collected simultaneously from the left main coronary artery and coronary sinus for measurement of Lp-PLA2, lysophosphatidylcholine (a product of Lp-PLA2), and C-reactive protein. Hemodynamic parameters and cholesterol were similar in both groups. Arterial Lp-PLA2 levels were similar in patients and control subjects: 225 ng/mL (interquartile range [IQR], 196 to 273 ng/mL) versus 221 ng/mL (IQR, 177 to 294 ng/mL). Lp-PLA2 net production in the coronary circulation was higher in patients compared with control subjects: 519 ng/min (IQR, 198 to 1276 ng/min) versus –529 ng/min (IQR, –872 to –79 ng/min; P=0.001) and correlated with percent atheroma volume (rs=0.37, P=0.04). Net production of lysophosphatidylcholine was higher in patients compared with control subjects: 199 ng/min (IQR, –592 to 470 ng/min) versus –505 ng/min (IQR, –1119 to 0 ng/min; P=0.03) and correlated with coronary endothelial dysfunction (rs=0.5, P=0.005). C-reactive protein was not significantly different between the groups.
Conclusions— Early coronary atherosclerosis in humans is characterized by local production of Lp-PLA2. Local coronary production of lysophosphatidylcholine, the active product of Lp-PLA2, is associated with endothelial dysfunction. These results support the role for Lp-PLA2 in the mechanism of regional vascular inflammation and atherosclerosis in humans.
CLINICAL PERSPECTIVE
Related Article:
-
Issue Highlights
Circulation 2007 115: 2683.[Extract] [Full Text]
This article has been cited by other articles:
 |
|
 |
|
  J. Herrmann, D. Mannheim, C. Wohlert, D. Versari, F. B. Meyer, J. P. McConnell, M. Gossl, L. O. Lerman, and A. Lerman Expression of lipoprotein-associated phospholipase A2 in carotid artery plaques predicts long-term cardiac outcome Eur. Heart J., December 1, 2009; 30(23): 2930 - 2938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Lavi, J-H Bae, C S Rihal, A Prasad, G W Barsness, R J Lennon, D R Holmes Jr, and A Lerman Segmental coronary endothelial dysfunction in patients with minimal atherosclerosis is associated with necrotic core plaques Heart, September 15, 2009; 95(18): 1525 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Vickers, C. T. Maguire, R. Wolfert, A. R. Burns, M. Reardon, R. Geis, P. Holvoet, and J. D. Morrisett Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis J. Lipid Res., September 1, 2009; 50(9): 1735 - 1743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. U. Eisenhardt, J. Habersberger, A. Murphy, Y.-C. Chen, K. J. Woollard, N. Bassler, H. Qian, C. von zur Muhlen, C. E. Hagemeyer, I. Ahrens, et al. Dissociation of Pentameric to Monomeric C-Reactive Protein on Activated Platelets Localizes Inflammation to Atherosclerotic Plaques Circ. Res., July 17, 2009; 105(2): 128 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cassar, P. Chareonthaitawee, C. S. Rihal, A. Prasad, R. J. Lennon, L. O. Lerman, and A. Lerman Lack of Correlation Between Noninvasive Stress Tests and Invasive Coronary Vasomotor Dysfunction in Patients With Nonobstructive Coronary Artery Disease Circ Cardiovasc Interv, June 1, 2009; 2(3): 237 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tsimikas, J. Willeit, M. Knoflach, M. Mayr, G. Egger, M. Notdurfter, J. L. Witztum, C. J. Wiedermann, Q. Xu, and S. Kiechl Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study Eur. Heart J., January 1, 2009; 30(1): 107 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Serruys, H. M. Garcia-Garcia, P. Buszman, P. Erne, S. Verheye, M. Aschermann, H. Duckers, O. Bleie, D. Dudek, H. E. Botker, et al. Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque Circulation, September 9, 2008; 118(11): 1172 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Jaffe Key Issues in the Developing Synergism between Cardiovascular Imaging and Biomarkers Clin. Chem., September 1, 2008; 54(9): 1432 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vinson, M. C. Mahaney, V. P. Diego, L. A. Cox, J. Rogers, J. L. VandeBerg, and D. L. Rainwater Genotype-by-diet effects on co-variation in Lp-PLA2 activity and LDL-cholesterol concentration in baboons fed an atherogenic diet J. Lipid Res., June 1, 2008; 49(6): 1295 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koenig Treating Residual Cardiovascular Risk: Will Lipoprotein-Associated Phospholipase A2 Inhibition Live Up to Its Promise? J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1642 - 1644. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lavi, E. H. Yang, A. Prasad, V. Mathew, G. W. Barsness, C. S. Rihal, L. O. Lerman, and A. Lerman The Interaction Between Coronary Endothelial Dysfunction, Local Oxidative Stress, and Endogenous Nitric Oxide in Humans Hypertension, January 1, 2008; 51(1): 127 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Sabatine, D. A. Morrow, M. O'Donoghue, K. A. Jablonksi, M. M. Rice, S. Solomon, Y. Rosenberg, M. J. Domanski, J. Hsia, and for the PEACE Investigators Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2463 - 2469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. White, P. Rastogi, and J. McHowat Lysoplasmenylcholine increases neutrophil adherence to human coronary artery endothelial cells Am J Physiol Cell Physiol, November 1, 2007; 293(5): C1467 - C1471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Saougos, A. P. Tambaki, M. Kalogirou, M. Kostapanos, I. F. Gazi, R. L. Wolfert, M. Elisaf, and A. D. Tselepis Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A2 Arterioscler Thromb Vasc Biol, October 1, 2007; 27(10): 2236 - 2243. [Abstract] [Full Text] [PDF]
|
|